Medicine and HealthCancer Medicine
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial
T. Sonoda, Y. Umeda, et al.
This Phase 2 study by Tomoaki Sonoda and colleagues investigates the efficacy and safety of nab-paclitaxel in advanced non-small cell lung cancer patients after PD-(L)1 inhibitor failure. With an impressive objective response rate of 55.2% and median overall survival of 11.9 months, the findings promise new hope in treating this challenging condition.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
B. Besse, E. Pons-tostivint, et al.
Medicine and Health
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer
Y. Zeng, C. Hu, et al.
Medicine and Health
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
M. Schuler, K. Cuppens, et al.
Medicine and Health
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study
J. An, X. Li, et al.
